Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia

Molecular Cancer Research

Volumn 1, Issue 2, 2002, Pages 89-95

  Ebos, John M L ^a,b   Tran, Jennifer ^a,c   Master, Zubin ^a,b   Dumont, Daniel ^a,b   Melo, Junia V ^d   Buchdunger, Elisabeth ^e   Kerbel, Robert S ^a,b,c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BCR ABL PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; INTERLEUKIN 3; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BONE MARROW CELL; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG TARGETING; GENE AMPLIFICATION; GENETIC TRANSFECTION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MEGAKARYOCYTE; ONCOGENE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL DIVISION; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; DENSITOMETRY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; FUSION PROTEINS, BCR-ABL; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-3; K562 CELLS; LEUKEMIA, MYELOID, CHRONIC; LYMPHOKINES; MICE; NEOVASCULARIZATION, PATHOLOGIC; PIPERAZINES; PRECIPITIN TESTS; PYRIMIDINES; TIME FACTORS; TRANSFECTION; UMBILICAL VEINS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

MURINAE;

EID: 0036928731     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Bouck, N., Stellmach, V., and Hsu, S. C. How tumors become angiogenic. Adv. Cancer Res., 69: 135-174, 1996.
2. Mazure, N. M., Chen, E. Y., Yeh, P., Laderoute, K. R., and Giaccia, A. J. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res., 56: 3436-3440, 1996.
3. Kerbel, R. S., Viloria-Petit, A. M., Okada, F., and Rak, J. W. Establishing a link between oncogenes and tumor angiogenesis. Mol. Med., 4: 286-295, 1998.
4. Volpert, O. V., Dameron, K. M., and Bouck, N. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene, 14: 1495-1502, 1997.
5. Rak, J., Mitsuhashi, Y., Bayko, L., Filmus, J., Sasazuki, T., and Kerbel, R. S. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res., 55: 4575-4580, 1995.
6. Grugel, S., Finkenzeller, G., Weindel, K., Barleon, B., and Marme, D. Both vHa-ras and v-raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J. Biol. Chem., 270: 25915-25919, 1995.
7. Viloria-Petit, A. M., Rak, J., Hung, M-C., Rockwell, P., Goldstein, N., and Kerbel, R. S. Neutralizing antibodies against EGF and ErbB-2/neu receptor tyrosine kinases down-regulate VEGF production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol., 151: 1523-1530, 1997.
8. Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B. Y., Hicklin, D. J., Radinsky, R., and Dinney, C. P. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res., 5: 257-265, 1999.
9. Bruns, C. J., Solorzano, C. C., Harbison, M. T., Ozawa, S., Tsan, R., Fan, D., Abbruzzese, J., Traxler, P., Buchdunger, E., Radinsky, R., and Fidler, I. J. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res., 60: 2926-2935, 2000.
10. Ciardiello, F., Bianco, R., Damiano, V., Fontanini, G., Caputo, R., Pomatico, G., De Placido, S., Bianco, A. R., Mendelsohn, J., and Tortora, G. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin. Cancer Res., 6: 3739-3747, 2000.
11. Druker, B. J. and Lydon, N. B. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest., 105: 3-7, 2000.
12. Bertolini, F., Mancuso, P., Gobbi, A., and Pruneri, G. The thin red line. Angiogenesis in normal and malignant hematopoiesis. Exp. Hematol., 28: 993-1000, 2000.
13. Bellamy, W. T., Richter, L., Frutiger, Y., and Grogan, T. M. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res., 59: 728-733, 1999.
14. Aguayo, A., Kantarjian, H., Manshouri, T., Gidel, C., Estey, E., Thomas, D., Koller, C., Estrov, Z., O'Brien, S., Keating, M., Freireich, E., and Albitar, M. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood, 96: 2240-2245, 2000.
15. Dias, S., Hattori, K., Zhu, Z., Heissig, B., Choy, M., Lane, W., Wu, Y., Chadburn, A., Hyjek, E., Gill, M., Hicklin, D. J., Witte, L., Moore, M. A., and Rafii, S. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J. Clin. Invest., 106: 511-521, 2000.
16. Janowska-Wieczorek, A., Majka, M., Marquez-Curtis, L., Wertheim, J. A., Turner, A. R., and Ratajczak, M. Z. Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants. Leukemia, 16: 1160-1166, 2002.
17. Arbiser, J. L., Moses, M. A., Fernandez, C. A., Ghiso, N., Cao, Y., Klauber, N., Frank, D., Brownlee, M., Flynn, E., Parangi, S., Byers, H. R., and Folkman, J. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc. Natl. Acad. Sci. USA, 94: 861-866, 1997.
18. Gerber, H. P., Dixit, V., and Ferrara, N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J. Biol. Chem., 273: 13313-13316, 1998.
19. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., and Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med., 2: 561-566, 1996.
20. Benjamin, M. F., Mow, B. M., Svingen, P. A., Hallgren, C. G., Weisberg, E., Kottke, T. J., Narayanan, V. L., Litzow, M. R., Griffin, J. D., Sausville, E. A., Tefferi, A., and Kaufmann, S. H. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood, 99: 664-671, 2002.
21. Mahon, F. X., Deininger, M. W., Schultheis, B, Chabrol, J., Reiffers, J., Goldman, J. M., and Melo, J. V. Selection and characterization of BCRABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood, 96: 1070-1079, 2000.
22. Weisberg, E. and Griffin, J. D. Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients. Drug Resist. Updates, 4: 22-28, 2001.
23. le Coutre, P., Tassi, E., Varella-Garcia, M., Bami, R., Mologni, L., Cabrita, G., Marchesi, E., Supino, R., and Gambacorti-Passerini, C. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood, 95: 1758-1766, 2000.
24. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., and Sawyers, C. L. Clinical resistance to STI-571 cancer therapy caused by BCRABL gene mutation or amplification. Science, 293: 876-880, 2001.
25. Viloria-Petit, A., Crombet, T., Jothy, S., Hicklin, D., Bohlen, P., Schlaeppi, J. M., Rak, J., and Kerbel, R. S. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res., 61: 5090-5101, 2001.
26. Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., and Jain, R. K. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature, 416: 279-280, 2002.
27. Franklin, W. A., Christison, W. H., Colley, M., Montag, A. G., Stephens, J. K., and Hart, C. E. In situ distribution of the β-subunit of platelet-derived growth factor receptor in nonneoplastic tissue and in soft tissue tumors. Cancer Res., 50: 6344-6348, 1990.
28. Nister, M., Claesson-Welsh, L., Eriksson, A., Heldin, C. H., and Westermark, B. Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines. J. Biol. Chem., 266: 16755-16763, 1991.
29. Hermanson, M., Funa, K., Hartman, M., Claesson-Welsh, L., Heldin, C. H., Westermark, B., and Nister, M. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res., 52: 3213-3219, 1992.
30. Guha, A., Dashner, K., Black, P. M., Wagner, J. A., and Stiles, C. D. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int. J. Cancer, 60: 168-173, 1995.
31. Guha, A., Glowacka, D., Carroll, R., Dashner, K., Black, P. M., and Stiles, C. D. Expression of platelet derived growth factor and platelet derived growth factor receptor mRNA in a glioblastoma from a patient with Li-Fraumeni syndrome. J. Neurol. Neurosurg. Psychiatry JID - 2985191R, 58: 711-714, 1995.
32. Apperley, J. F., Gardembas, M., Melo, J. V., Russell-Jones, R., Bain, B. J., Baxter, E. J., Chase, A., Chessells, J. M., Colombat, M., Dearden, C. E., Dimitrijevic, S., Mahon, F. X., Marin, D., Nikolova, Z., Olavarria, E., Silberman, S., Schultheis, B., Cross, N. C., and Goldman, J. M. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor β. N. Engl. J. Med., 347: 481-487, 2002.
33. Magnusson, M. K., Meade, K. E., Nakamura, R., Barrett, J., and Dunbar, C. E. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor β-receptor fusion oncogene. Blood, 100: 1088-1091, 2002.
34. Daley, G. Q. and Baltimore, D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/ abl protein. Proc. Natl. Acad. Sci. USA, 85: 9312-9316, 1988.
35. Avanzi, G. C., Lista, P., Giovinazzo, B., Miniero, R., Saglio, G., Benetton, G., Coda, R., Cattoretti, G., and Pegoraro, L. Selective growth response to IL-3 of a human leukaemic cell line with megakaryoblastic features. Br. J. Haematol., 69: 359-366, 1988.
36. Greenberger, J. S., Sakakeeny, M. A., Humphries, R. K., Eaves, C. J., and Eckner, R. J. Demonstration of permanent factor-dependent multipotential (erythroid/neutrophil/basophil) hematopoietic progenitor cell lines. Proc. Natl. Acad. Sci. USA, 80: 2931-2935, 1983.
37. Tran, J., Master, Z., Yu, J., Rak, J., Dumont, D. J., and Kerbel, R. S. A role for surviving in chemoresistance of endothelial cells mediated by VEGF. Proc. Natl. Acad. Sci. USA, 99: 4349-4354, 2002.
38. Jones, N. and Dumont, D. J. The Tek/Tie2 receptor signals through a novel Dok-related docking protein, Dok-R. Oncogene, 17: 1097-1108, 1998.